Articles By Jack Cush, MD
Post-Arthroscopic Increase in Septic Arthritis
By Jack Cush, MD
27 September 2021
A longitudinal study from Iceland shows an increasing number of native joint infections (NJI), with iatrogenic, postarthroscopic infections being of particular concern.
Read Article
Is Acetaminophen Potentially Hazardous in Pregnancy?
By Jack Cush, MD
27 September 2021
A consensus report from a multinational group of 91 scientists, clinicians and public health professionals alarmed the medical world last week as they suggest the use of acetaminophen (paracetamol) during pregnancy may have hazardous developmental effects on the fetus.
Read Article
RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)
By Jack Cush, MD
23 September 2021
Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID breakthrough infections, and statin use and the risk of RA, as I review the news and journal articles from the past week on RheumNow.
Read Article
Guselkumab Treats Axial Disease in Psoriatic Arthritis
By Jack Cush, MD
23 September 2021
Pooled analysis of the DISCOVER-1 and DISCOVER-2 trials have shown that guselkumab, an IL-23 inhibitor, was effective and safe in psoriatic arthritis (PsA) patients with axial involvement and imaging-confirmed sacroiliitis.
Read Article
11 Drugs That Cause Arthritis
By Jack Cush, MD
23 September 2021
This is the #1 question I get from new consults: “How did I get arthritis?” But as aching patients ask this question, they are really thinking these joint complaints must be due to something.
Read Article
IL-6 Inhibition in Refractory Systemic Sclerosis
By Jack Cush, MD
22 September 2021
A small, single-center cohort analysis of difficult, refractory systemic sclerosis (SSc) patients showed that treatment with tocilizumab (TCZ), an interleukin-6 inhibitor, resulted in significant improvement in joint and skin involvement, regardless of SSc disease duration or subtype.
Read Article
Tocilizumab and Drug Shortage Headaches
By Jack Cush, MD
22 September 2021
Do you know what’s in short supply? Trust, pediatric rheumatologists, and drugs. Since the onset of the pandemic, numerous drug shortages have affected rheumatology, including sulfasalazine, hydroxychloroquine, and now, tocilizumab.
Read Article
High Comorbidity Rates with Inclusion Body Myositis
By Jack Cush, MD
21 September 2021
Inclusion body myositis (IBM) patients tend to be older than those with idiopathic inflammatory myositis (IIM), but the scope of disease beyond their myositis is not appreciated.
Read Article
Worrisome Maternal Mortality with COVID-19 Infection
By Jack Cush, MD
20 September 2021
Maternal and fetal outcomes during the COVID-19 pandemic have not been well studied; yet a new retrospective study from Mexico indicates that during the pandemic maternal mortality increased by nearly 57%, with COVID-19 as the cause in 23% of cases.
Read Article
RheumNow Podcast – Do More DMARDs Mean More Switching? (9.17.2021)
By Jack Cush, MD
16 September 2021
Smartphones and diet; COVID-19 and the numbers - reassuring or not, and what about masks?; and do more drugs mean more switching, less persistence, and patient adherence goes up...or down? All this and more news and journal reports in this week's episode.
Read Article